How does medical purpose drive regulatory requirements in EU clinical trials?
Clear and accurate assessment of whether use of an assay in a clinical trial assay is considered exploratory or an “IVD” is necessary as implications extend to quality/regulatory pathways, assay de
James Yen
FedEx Express National Service Disruption: Severe Winter Weather
FedEx Express experienced substantial disruptions at their Memphis and Indianapolis hubs last night due to severe winter weather that has been moving across the United States.
Lite Paper: Real-World PD-L1 Testing Data Provides Insight into the Evolving Immuno-oncology Landscape
Case Study: How Pharma Uses NeoGenomics Real-World Oncology Data to Accelerate Biomarker Adoption and Commercial Launch
Taking Spatial Toward the Clinic: DeciBio’s Q&A with Sandy Au of NeoGenomics
Blog originally posted on Decibio Insights here.
Is IHC going to exhaust our archival blocks the way single gene testing used to?
Over the past year we have seen unprecedented demand for IHC assay development services with the goal of creating a prototype CDx assay.
NeoGenomics announces speaker program, ‘Minimal Residual Disease in Colorectal Cancer’
NeoGenomics is pleased to announce a speaker program titled ‘Minimal Residual Disease in Colorectal Cancer.’